Collateral metabolic vulnerabilities unveiled by loss of isozyme diversity in breast cancer.

乳腺癌中同工酶多样性的丧失揭示了伴随的代谢脆弱性。

阅读:4
作者:
BACKGROUND: Loss of isozyme diversity (LID) refers to the selective dependency on a single isozyme following the functional collapse of its redundant counterparts, uncovering a metabolic vulnerability. This metabolic liability establishes LID as a novel framework for precision targeting strategy in cancer therapy. METHODS: We integrated a large-scale breast cancer multi-omics cohort to systematically delineate isozyme expression patterns and identify therapeutically promising LID targets across intrinsic molecular subtypes. Genomic and epigenetic data were employed to decipher the underlying causes of LID. Subsequent experiments were conducted to validate the collateral metabolic vulnerabilities arising from identified LID targets and investigate the associated mechanisms. RESULTS: Our analysis delineated the isozyme utilization patterns for metabolic reactions in breast cancer, which revealed widespread and significant LID phenomena. We further decoded the enrichment characteristics of these LID reactions and identified a set of potential clinically relevant LID targets across different subtypes. Further investigation revealed that copy number loss and epigenetic silencing predominantly drive these LIDs, as exemplified by luminal subtype-specific N-myristoyltransferase 2 (NMT2) deficiency caused by hypermethylation. Mechanistic studies demonstrated that NMT2 deficiency confers synthetic lethality with NMT1 inhibition, potentially through impaired myristoylation of the oncogenic effector FMR1 autosomal homolog 2 (FXR2). These findings underscored the potential of NMT inhibitors as viable therapeutic strategies for NMT2-deficient tumors. CONCLUSIONS: In conclusion, this study constructed a comprehensive LID landscape across all breast cancer subtypes, advancing precision oncology through innovative metabolic targeting approaches. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-025-01573-y.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。